Published in J Bone Miner Res on October 01, 1995
Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int (2008) 3.80
Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest (1999) 3.30
Bisphosphonates: mechanisms of action. J Clin Invest (1996) 2.83
Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci U S A (1999) 2.66
Regulation of osteoclast apoptosis by ubiquitylation of proapoptotic BH3-only Bcl-2 family member Bim. EMBO J (2003) 2.30
The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer (2001) 2.14
Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer (2000) 2.12
Loss of estrogen upregulates osteoblastogenesis in the murine bone marrow. Evidence for autonomy from factors released during bone resorption. J Clin Invest (1998) 1.73
Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoclasts. J Exp Med (1997) 1.68
Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo. J Bone Miner Res (2008) 1.68
A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Br J Pharmacol (2006) 1.67
Bone resorption induced by parathyroid hormone is strikingly diminished in collagenase-resistant mutant mice. J Clin Invest (1999) 1.67
Development of bisphosphonates. Breast Cancer Res (2001) 1.63
Osteonecrosis of the jaw in a patient on Denosumab. J Oral Maxillofac Surg (2010) 1.59
Red light of 647 nm enhances osteogenic differentiation in mesenchymal stem cells. Lasers Med Sci (2008) 1.57
Novel therapy to reverse the cellular effects of bisphosphonates on primary human oral fibroblasts. J Oral Maxillofac Surg (2011) 1.50
Bisphosphonates cause osteonecrosis of the jaw-like disease in mice. Am J Pathol (2010) 1.40
The epidemiology of distal radius fractures. Hand Clin (2012) 1.40
Bone metastasis in gastric cancer patients. J Gastric Cancer (2011) 1.33
Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment. BMC Cancer (2006) 1.23
Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br J Cancer (2003) 1.21
Genetic evidence for a role for Src family kinases in TNF family receptor signaling and cell survival. Genes Dev (2001) 1.17
Osteoclast precursor interaction with bone matrix induces osteoclast formation directly by an interleukin-1-mediated autocrine mechanism. J Biol Chem (2008) 1.16
Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone. BMC Cancer (2010) 1.13
New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects. Br J Cancer (2003) 1.10
Suppression of osteoclastogenesis through phosphorylation of eukaryotic translation initiation factor 2 alpha. J Bone Miner Metab (2013) 1.08
The acidocalcisome as a target for chemotherapeutic agents in protozoan parasites. Curr Pharm Des (2008) 1.05
Bisphosphonates antagonise bone growth factors' effects on human breast cancer cells survival. Br J Cancer (2003) 1.05
Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis. Support Care Cancer (2006) 1.05
Osteoclasts have multiple roles in bone in addition to bone resorption. Crit Rev Eukaryot Gene Expr (2009) 1.03
Isoprenoid biosynthetic pathway inhibition disrupts monoclonal protein secretion and induces the unfolded protein response pathway in multiple myeloma cells. Leuk Res (2010) 1.03
Vacuolar proton pyrophosphatase activity and pyrophosphate (PPi) in Toxoplasma gondii as possible chemotherapeutic targets. Biochem J (2000) 1.02
Advances in osteoclast biology reveal potential new drug targets and new roles for osteoclasts. J Bone Miner Res (2013) 0.99
Immortalization of osteoclast precursors by targeting Bcl -XL and Simian virus 40 large T antigen to the osteoclast lineage in transgenic mice. J Clin Invest (1998) 0.99
Direct effects of bisphosphonates on breast cancer cells. Breast Cancer Res (2001) 0.98
Apoptosis in bone physiology and disease. Mol Pathol (1997) 0.98
Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid. J Bone Miner Metab (2009) 0.98
The inhibitory effect of alendronate, a nitrogen-containing bisphosphonate on the PI3K-Akt-NFkappaB pathway in osteosarcoma cells. Br J Pharmacol (2005) 0.95
Reveromycin A, an agent for osteoporosis, inhibits bone resorption by inducing apoptosis specifically in osteoclasts. Proc Natl Acad Sci U S A (2006) 0.94
Synthesis and biological evaluation of 2-alkylaminoethyl-1,1-bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl diphosphate synthase. Bioorg Med Chem (2007) 0.93
Engineering mesenchymal stem cells for regenerative medicine and drug delivery. Methods (2015) 0.93
The bisphosphonate pamidronate induces apoptosis in human melanoma cells in vitro. Br J Cancer (2002) 0.92
The combination therapy with alfacalcidol and risedronate improves the mechanical property in lumbar spine by affecting the material properties in an ovariectomized rat model of osteoporosis. BMC Musculoskelet Disord (2009) 0.91
Alendronate enhances osteogenic differentiation of bone marrow stromal cells: a preliminary study. Clin Orthop Relat Res (2008) 0.91
A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo. Br J Cancer (2006) 0.91
Bisphosphonate administration prior to tooth extraction delays initial healing of the extraction socket in rats. J Bone Miner Metab (2009) 0.91
RANKL increases the level of Mcl-1 in osteoclasts and reduces bisphosphonate-induced osteoclast apoptosis in vitro. Arthritis Res Ther (2009) 0.91
Bisphosphonate-associated osteonecrosis of the jaw: the rheumatologist's role. Arthritis Res Ther (2006) 0.90
Bisphosphonate-associated osteonecrosis of the jaw: what do we currently know? A survey of knowledge given in the recent literature. Clin Oral Investig (2009) 0.90
Zoledronic acid inhibits RANK expression and migration of osteoclast precursors during osteoclastogenesis. Naunyn Schmiedebergs Arch Pharmacol (2011) 0.90
The role of bisphosphonates in diseases of childhood. Eur J Pediatr (2003) 0.89
Regulation of osteoclast polarization. Odontology (2007) 0.89
Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. Osteoporos Int (2006) 0.89
Increased risk of dementia in patients with osteoporosis: a population-based retrospective cohort analysis. Age (Dordr) (2013) 0.88
Synthesis and biological evaluation of new 2-alkylaminoethyl-1,1-bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl diphosphate synthase. Bioorg Med Chem (2011) 0.88
Osteoclast abnormalities in fractured bone during bisphosphonate treatment for osteoporosis: a case report. Skeletal Radiol (2012) 0.87
Gallium modulates osteoclastic bone resorption in vitro without affecting osteoblasts. Br J Pharmacol (2010) 0.87
Consequences of irradiation on bone and marrow phenotypes, and its relation to disruption of hematopoietic precursors. Bone (2014) 0.87
Differential activities of thalidomide and isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells. Leuk Res (2009) 0.87
Influence of bisphosphonates on the osteoblast RANKL and OPG gene expression in vitro. Clin Oral Investig (2010) 0.86
In vitro and in vivo assays for osteoclast apoptosis. Biol Proced Online (2005) 0.86
Strategies of spinal fusion on osteoporotic spine. J Korean Neurosurg Soc (2011) 0.86
Long Term Cyclic Pamidronate Reduces Bone Growth by Inhibiting Osteoclast Mediated Cartilage-to-Bone Turnover in the Mouse. Open Orthop J (2008) 0.85
Bisphosphonates and bone quality. Bonekey Rep (2014) 0.85
Design, synthesis, calorimetry, and crystallographic analysis of 2-alkylaminoethyl-1,1-bisphosphonates as inhibitors of Trypanosoma cruzi farnesyl diphosphate synthase. J Med Chem (2012) 0.84
CONNEXIN 43 AND BONE: NOT JUST A GAP JUNCTION PROTEIN. Actual osteol (2011) 0.84
1-(Fluoroalkylidene)-1,1-bisphosphonic acids are potent and selective inhibitors of the enzymatic activity of Toxoplasma gondii farnesyl pyrophosphate synthase. Org Biomol Chem (2012) 0.84
Role of connexin 43 in the mechanism of action of alendronate: dissociation of anti-apoptotic and proliferative signaling pathways. Arch Biochem Biophys (2012) 0.84
High-frequency loading positively impacts titanium implant osseointegration in impaired bone. Osteoporos Int (2014) 0.83
Osteoclast responses to lipopolysaccharide, parathyroid hormone and bisphosphonates in neonatal murine calvaria analyzed by laser scanning confocal microscopy. J Histochem Cytochem (2005) 0.83
Drugs in development: bisphosphonates and metalloproteinase inhibitors. Arthritis Res Ther (2002) 0.83
OPG-Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice. J Bone Miner Res (2015) 0.83
Bisphosphonates significantly increase the activity of doxorubicin or vincristine against canine malignant histiocytosis cells. Vet Comp Oncol (2011) 0.82
Bisphosphonate-induced differential modulation of immune cell function in gingiva and bone marrow in vivo: role in osteoclast-mediated NK cell activation. Oncotarget (2015) 0.82
Alendronate reduces osteoclast precursors in osteoporosis. Osteoporos Int (2009) 0.82
Small interfering RNA knocks down the molecular target of alendronate, farnesyl pyrophosphate synthase, in osteoclast and osteoblast cultures. Mol Pharm (2011) 0.82
ONO-5334, a cathepsin K inhibitor, improves bone strength by preferentially increasing cortical bone mass in ovariectomized rats. J Bone Miner Metab (2013) 0.81
Safety of denosumab in postmenopausal women with osteoporosis or low bone mineral density: a meta-analysis. Int J Clin Exp Pathol (2014) 0.81
Clinical experience with intravenous zoledronic acid in the treatment of male osteoporosis: evidence and opinions. Ther Adv Musculoskelet Dis (2013) 0.81
Bisphosphonate-related osteonecrosis of the jaw in non-malignant bone disease. Rheumatol Int (2013) 0.81
Bisphosphonate associated osteonecrosis of the jaw: an update on pathophysiology, risk factors, and treatment. Int J Dent (2014) 0.81
Inhibition of inflammatory actions of aminobisphosphonates by dichloromethylene bisphosphonate, a non-aminobisphosphonate. Br J Pharmacol (1999) 0.80
Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients. Wien Klin Wochenschr (2006) 0.80
Bisphosphonates in bone cement inhibit PMMA particle induced bone resorption. Ann Rheum Dis (1998) 0.79
Attenuated monocyte apoptosis, a new mechanism for osteoporosis suggested by a transcriptome-wide expression study of monocytes. PLoS One (2015) 0.79
Contemporary agents in the management of metastatic castration-resistant prostate cancer. Can Urol Assoc J (2016) 0.79
Extracellular calcium increases bisphosphonate-induced growth inhibition of breast cancer cells. Breast Cancer Res (2008) 0.79
Adjuvant pamidronate therapy prevents the development of bone metastases in breast cancer patients with four or more positive nodes. Oncol Lett (2010) 0.79
Denosumab: a new agent in the management of hypercalcemia of malignancy. Future Oncol (2015) 0.79
CCN1, a candidate target for zoledronic acid treatment in breast cancer. Mol Cancer Ther (2011) 0.79
Use of zoledronic acid in the treatment of Paget's disease. Ther Clin Risk Manag (2007) 0.78
The effect of zoledronic acid on the volume of the fusion-mass in lumbar spinal fusion. Clin Orthop Surg (2013) 0.78
A Biphasic Calcium Sulphate/Hydroxyapatite Carrier Containing Bone Morphogenic Protein-2 and Zoledronic Acid Generates Bone. Sci Rep (2016) 0.78
Reveromycin A Administration Prevents Alveolar Bone Loss in Osteoprotegerin Knockout Mice with Periodontal Disease. Sci Rep (2015) 0.78
Bisphosphonate treatment of benign multifocal and unifocal osteolytic tumours of bone. Sarcoma (2003) 0.78
Apoptosis in interface membranes of aseptically loose total hip arthroplasty. J Mater Sci Mater Med (2001) 0.78
Osteoanabolic effect of alendronate and zoledronate on bone marrow stromal cells (BMSCs) isolated from aged female osteoporotic patients and its implications for their mode of action in the treatment of age-related bone loss. Osteoporos Int (2013) 0.78
Apoptosis during intramembranous ossification. J Anat (2003) 0.78
Dexamethasone inhibits bone resorption by indirectly inducing apoptosis of the bone-resorbing osteoclasts via the action of osteoblastic cells. Cytotechnology (2001) 0.78
Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature (1986) 5.68
Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev (1997) 5.65
TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest (1999) 5.30
Metastatic prostate cancer in a transgenic mouse. Cancer Res (1996) 4.02
The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J (1999) 3.77
Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest (1996) 3.44
Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest (1992) 3.40
Negative regulation of cytokine signaling pathways. Annu Rev Immunol (2000) 2.98
Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Engl J Med (1974) 2.97
Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med (1996) 2.92
Oxygen-derived free radicals stimulate osteoclastic bone resorption in rodent bone in vitro and in vivo. J Clin Invest (1990) 2.92
Spred is a Sprouty-related suppressor of Ras signalling. Nature (2001) 2.87
Mineralisation defects with pamidronate therapy for Paget's disease. Lancet (1993) 2.76
Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol (1998) 2.73
Successful en-bloc resection of large superficial tumors in the stomach and colon using sodium hyaluronate and small-caliber-tip transparent hood. Endoscopy (2003) 2.67
Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures. Endocrinology (1988) 2.60
Tumor necrosis factors alpha and beta induce osteoblastic cells to stimulate osteoclastic bone resorption. J Immunol (1987) 2.59
Establishment of an osteocyte-like cell line, MLO-Y4. J Bone Miner Res (1997) 2.55
Cloning and characterization of novel CIS family genes. Biochem Biophys Res Commun (1997) 2.51
Two cis-acting elements in the 3' untranslated region of alpha-CaMKII regulate its dendritic targeting. Nat Neurosci (2000) 2.34
The hypercalcemia of cancer. Clinical implications and pathogenic mechanisms. N Engl J Med (1984) 2.33
Detection of measles virus nucleocapsid transcripts in circulating blood cells from patients with Paget disease. J Bone Miner Res (1996) 2.33
'Small worlds' and the evolution of virulence: infection occurs locally and at a distance. Proc Biol Sci (1999) 2.31
Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest (2003) 2.30
Modulation of type beta transforming growth factor activity in bone cultures by osteotropic hormones. Proc Natl Acad Sci U S A (1987) 2.29
Contribution of carbohydrate antigens sialyl Lewis A and sialyl Lewis X to adhesion of human cancer cells to vascular endothelium. Cancer Res (1993) 2.24
SOCS3 is essential in the regulation of fetal liver erythropoiesis. Cell (1999) 2.19
Primary hyperparathyroidism: changes in the pattern of clinical presentation. Lancet (1980) 2.19
Differential roles for bone morphogenetic protein (BMP) receptor type IB and IA in differentiation and specification of mesenchymal precursor cells to osteoblast and adipocyte lineages. J Cell Biol (1998) 2.17
Presenilin-1 mutations downregulate the signalling pathway of the unfolded-protein response. Nat Cell Biol (1999) 2.14
Bone-resorbing activity in supernatants from lymphoid cell lines. N Engl J Med (1974) 2.08
Rescue of osteoclast function by transgenic expression of kinase-deficient Src in src-/- mutant mice. Genes Dev (1997) 2.08
Effects of interleukin-1 on bone turnover in normal mice. Endocrinology (1989) 2.06
Pathogen invasion and host extinction in lattice structured populations. J Math Biol (1994) 2.05
The hypercalcemia of malignancy: pathogenesis and management. Metabolism (1982) 2.01
Continuous ambulatory radionuclide monitoring of left ventricular function: effect of body position during ergometer exercise. J Nucl Med (1997) 1.99
Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res (1995) 1.97
Evolutionarily stable mutation rate in a periodically changing environment. Genetics (1989) 1.96
EUS in cirrhotic patients with and without prior variceal hemorrhage in comparison with noncirrhotic control subjects. Gastrointest Endosc (2000) 1.94
Actions of recombinant interleukin 1, interleukin 2, and interferon-gamma on bone resorption in vitro. J Immunol (1986) 1.93
Osteopetrosis in Src-deficient mice is due to an autonomous defect of osteoclasts. Proc Natl Acad Sci U S A (1993) 1.92
Interleukin-1 and tumor necrosis factor stimulate the formation of human osteoclastlike cells in vitro. J Bone Miner Res (1989) 1.87
Large shifts in pathogen virulence relate to host population structure. Science (2004) 1.84
Factors associated with humoral hypercalcemia of malignancy stimulate adenylate cyclase in osteoblastic cells. J Clin Invest (1983) 1.84
Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells. N Engl J Med (1987) 1.82
Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo. J Clin Invest (1995) 1.79
MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone (2004) 1.79
Decreased c-Src expression enhances osteoblast differentiation and bone formation. J Cell Biol (2000) 1.77
IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. J Immunol (1990) 1.77
Cancer and bone. Endocr Rev (1998) 1.77
Enhancement of intracellular growth of Mycobacterium tuberculosis in human monocytes by transforming growth factor-beta 1. J Infect Dis (1994) 1.76
In vivo effect of anti-asialo GM1 antibody on natural killer activity. Nature (1981) 1.71
Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood (2000) 1.69
Human recombinant transforming growth factor alpha stimulates bone resorption and inhibits formation in vitro. Proc Natl Acad Sci U S A (1986) 1.69
Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor. J Clin Invest (1995) 1.68
A Janus kinase inhibitor, JAB, is an interferon-gamma-inducible gene and confers resistance to interferons. Blood (1998) 1.68
Bone resorption induced by parathyroid hormone is strikingly diminished in collagenase-resistant mutant mice. J Clin Invest (1999) 1.67
Effects of human recombinant CSF-GM and highly purified CSF-1 on the formation of multinucleated cells with osteoclast characteristics in long-term bone marrow cultures. J Bone Miner Res (1986) 1.64
Osteolytic bone metastasis in breast cancer. Breast Cancer Res Treat (1994) 1.61
Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood (2001) 1.60
Interleukin-6: a potential mediator of the massive osteolysis in patients with Gorham-Stout disease. J Clin Endocrinol Metab (1996) 1.59
Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity. Blood (2000) 1.59
Dual role for the latent transforming growth factor-beta binding protein in storage of latent TGF-beta in the extracellular matrix and as a structural matrix protein. J Cell Biol (1995) 1.58
The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res (2001) 1.57
Involvement of hepcidin in the anemia of multiple myeloma. Clin Cancer Res (2008) 1.57
Activation of the bone-derived latent TGF beta complex by isolated osteoclasts. Biochem Biophys Res Commun (1989) 1.56
Chinese hamster ovarian cells transfected with the murine interleukin-6 gene cause hypercalcemia as well as cachexia, leukocytosis and thrombocytosis in tumor-bearing nude mice. Endocrinology (1991) 1.56
Role of transforming growth factor-beta in bone remodeling. Clin Orthop Relat Res (1990) 1.55
Smad5 and DPC4 are key molecules in mediating BMP-2-induced osteoblastic differentiation of the pluripotent mesenchymal precursor cell line C2C12. J Biol Chem (1998) 1.54
Tumor necrosis factor alpha is a cytotoxin induced by murine Chlamydia trachomatis infection. Infect Immun (1989) 1.54
The role of cadherin in the generation of multinucleated osteoclasts from mononuclear precursors in murine marrow. J Clin Invest (1995) 1.53
Alteration of vitamin D metabolism in Mexican-Americans. J Bone Miner Res (1990) 1.53
The evolution of parasite virulence and transmission rate in a spatially structured population. J Theor Biol (2000) 1.53
A murine model of human myeloma bone disease. Bone (1997) 1.53
Preventive effects of cyclosporin on diabetes in NOD mice. Diabetologia (1986) 1.52
Tumor-derived growth factor increases bone resorption in a tumor associated with humoral hypercalcemia of malignancy. Science (1983) 1.52